Group 1 - The core viewpoint of the article is that Insilico Medicine (03696.HK) has entered into a strategic drug development collaboration with Kangji Medical (00867.HK) to leverage AI in innovative drug development for central nervous system and autoimmune diseases [1] - The collaboration will involve at least two research projects that will utilize Insilico's validated AI platform and drug development capabilities, combined with Kangji's experienced research team and deep understanding of disease areas [1] - Insilico is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]